Showing posts with label Raise. Show all posts
Showing posts with label Raise. Show all posts

Thursday, 3 October 2013

Long Periods of Delirium in ICU May Raise Risk of Mental Impairment

News Picture: Long Periods of Delirium in ICU May Raise Risk of Mental ImpairmentBy Dennis Thompson
HealthDay Reporter

WEDNESDAY, Oct. 2 (HealthDay News) -- Patients who suffer longer bouts of delirium during lengthy stays in an intensive care unit stand a higher chance of developing mental deficits similar to those seen with a brain injury or early Alzheimer's disease, new research says.

Two of every five critical care patients developed thinking and memory difficulties like those in people with traumatic brain injuries after just three months' stay, while one in four had mental impairments similar to those seen in people with mild Alzheimer's.

"Even though our survival after critical illness has improved, a significant number of patients will suffer cognitive [mental] impairment after spending a long period in an ICU," said study author Dr. Pratik Pandharipande, a professor of anesthesiology and surgery at Vanderbilt University Medical Center in Nashville.

Delirium appeared to play the main role in this mental impairment, the researchers found. The more time an ICU patient spent in a state of delirium, the more likely that patient was to suffer thinking or memory problems.

"That provides us with the potential to reduce the duration of delirium we see in ICU patients," Pandharipande said. "That may impact the cognitive impairment we see after critical illness."

The study, which is published in the Oct. 3 issue of the New England Journal of Medicine, involved 821 ICU patients. Researchers monitored their progress and tested their ability to plan and solve problems at regular intervals.

At three months, 40 percent of patients displayed scores similar to patients with moderate traumatic brain injury and 26 percent had scores similar to those for patients with mild Alzheimer's.

These mental deficits persisted. A year later, about 34 percent of patients had scores similar to people with brain injuries and 24 percent had scores similar to those with mild Alzheimer's, the investigators found.

There didn't seem to be any particular type of patient more likely to suffer from impairment, Pandharipande said. The researchers found no significant differences based on gender, age or pre-existing health problems. Medical and surgical ICU patients both showed the same amount of risk.

"There was not a particular patient population that got separated out," he said. "All populations had the same risk of having cognitive impairment."

A long period of delirium was the only common denominator among those suffering impairment, the researchers noted.

"We think it's a brain organ dysfunction," Pandharipande said. "Delirium has been associated with cerebral atrophy, inflammation and changes in the brain's white matter. All these potentially could be the connection between delirium and long-term cognitive impairment."

While the study found an association between long periods of delirium and later mental impairment, it did not prove a cause-and-effect link.

Critical care physicians have been wrangling with this problem for decades, said Nancy Foster, vice president for quality and patient safety policy at the American Hospital Association, in Washington, D.C.

"This is a helpful look at an issue that has long puzzled clinicians and hospital leaders -- what leads to some patients having continuing cognitive problems after being released from an ICU," Foster said. "It's really helping identify where further focus should be placed while we unravel the mystery here."

Pandharipande said critical care physicians should consider taking steps to limit the amount of time patients spend in a delirious state. Moderating the use of sedatives, working to keep patients awake and active, and getting them mobile as soon as possible all could help stave off the potential damage of delirium.

Physicians also might consider how to best prepare a person mentally, as well as physically, to leave the hospital.

"Perhaps at the back end of ICU we should start doing a cognitive rehabilitation at the same time we provide physical rehabilitation," he said.

MedicalNews
Copyright © 2013 HealthDay. All rights reserved. SOURCES: Pratik Pandharipande, M.D., professor, anesthesiology and surgery, Vanderbilt University Medical Center, Nashville, Tenn.; Nancy Foster, vice president, quality and patient safety policy, American Hospital Association, Washington, D.C.; Oct. 3, 2013, New England Journal of Medicine



View the original article here

Tuesday, 25 June 2013

Stop-Smoking Therapies Raise Quitting Odds

Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
By Kathleen Struck, Senior Editor, MedPage Today

The use of smoking cessation treatments improved smokers' chances of quitting, a systematic review and meta-analysis showed.

Both nicotine replacement therapy (NRT) and bupropion were superior to placebo in helping patients quit (odds ratio [OR] for NRT 1.84, 95% CI 1.71-1.99; OR for bupropion 1.82, 95% CI 1.60-2.06), wrote Kate Cahill of the University of Oxford in England, and colleagues.

When compared against one another, NRT and bupropion showed equal efficacy (OR 0.99, 95% CI 0.86-1.13), they wrote online in the Cochrane Database of Systematic Reviews.

Use of varenicline, cytisine and nortriptyline also improved the chances of quitting, they noted.

The reviews were conducted between 2008 and 2012, analyzing 267 trials covering 101,804 smokers. Treatments studied included NRT, antidepressants (bupropion and nortriptyline), nicotine receptor partial agonists (varenicline and cytisine), anxiolytics, selective type 1 cannabinoid, receptor antagonists (rimonabant), clonidine, lobeline, dianicline, mecamylamine, Nicobrevin, opioid antagonists, nicotine vaccines, and silver acetate.

All the reviews used randomized controlled trials, and compared treatment with placebo and sometimes with other treatments, the authors wrote. A successful outcome was defined as 6 months' smoking cessation from the end of treatment.

Varenicline increased the odds of quitting compared with placebo (OR 2.88, 95% CI 2.40-3.47). It also showed superiority to single forms of NRT and to bupropion, they stated.

Varenicline also emerged as more effective than the nicotine patch, nicotine gum, and NRT inhaler, spray, tablets, and lozenges, the review stated. However, it was not more effective than combinations of NRT.

Combination NRT also outperformed single formulations. NRT inhaler, spray, tablets, and lozenges performed similarly against each other; all were marginally more effective than NRT gum (OR 1.21, 95% CI 1.01-1.46), the review found.

The nicotine receptor partial agonist cytisine -- available only in Russia and Eastern Europe -- returned positive findings (RR 3.98, 95% CI 2.01-7.87) without significant or serious adverse events, the authors reported.

The antidepressant nortriptyline also increased the chances of quitting (RR 2.03, 95% CI 1.48-2.78). Neither nortriptyline nor bupropion were shown to enhance the effect of NRT compared with NRT alone, they wrote.

Although most treatments did not appear to have adverse events that would mitigate their use, that was not the case with clonidine, the authors wrote. Clonidine increased the chances of quitting (RR 1.63, 95% CI 1.22-2.18), but was negated by a dose-dependent rise in adverse events.

They also found that mecamylamine combined with NRT may increase the chances of quitting, but the evidence remained inconclusive. Other treatments failed to demonstrate a benefit compared with placebo.

Nicotine vaccines are not yet licensed in the U.S. for smoking cessation. Nicobrevin's UK license has been revoked, and the manufacturers of rimonabant, taranabant and dianicline are no longer developing or testing those treatments, the authors noted.

The authors said their meta-analysis was limited by how recent the source reviews were. They also noted that "We have not included NRT in our meta-analyses of [serious adverse events], since coverage of this information was patchy or absent from many trial reports."

Funding was provided by the Department of Primary Care Health Sciences at the University of Oxford, the National School for Health Research School for Primary Care Research, and the National Institute for Health Research.

The authors of the overview contributed to many of the included reviews.

Kathleen Struck

Senior Editor

Kathleen Struck joined MedPage Today after serving as Managing Editor for EverydayHealth.com, Stars and Stripes and MediaNews Group. She lived and traveled internationally for more than 15 years and has written and edited for publications including, Washington Post, Baltimore Sun, Newsday and Regulatory Affairs Professional Society. At MedPage Today, she reports and edits on general news and information.